Association of alpha-1-adrenergic antagonist use with the risk of gout development in benign prostatic hyperplasia patients: a population-based cohort study.
Wei-Hung HsuJung-Nien LaiCheng-Li LinChing-Hui LohHuei-Kai HuangLiang-Kai HuangPublished in: Family practice (2022)
Patients who received more doses of alpha-1-adrenergic antagonists per year had a higher risk of developing gout. A causal proof of the role of alpha-1-adrenergic antagonists use in gout development should be analysed in future studies designed as double blind randomized controlled trials.
Keyphrases
- benign prostatic hyperplasia
- uric acid
- end stage renal disease
- lower urinary tract symptoms
- randomized controlled trial
- newly diagnosed
- ejection fraction
- chronic kidney disease
- clinical trial
- double blind
- prognostic factors
- peritoneal dialysis
- systematic review
- patient reported outcomes
- current status
- study protocol
- open label
- case control
- phase ii